Patiromer is a nonabsorbed, cation exchange polymer that contains a calcium-sorbitol counterion. Absorption. Binds and removes potassium from the GI tract, particularly the colon. Each packet of Veltassa contains 8.4 grams, 16.8 grams or 25.2 grams of patiromer, the active moiety. Drug classes that are known to cause hyperkalemia are listed below (table 1). There are 3 major mechanisms of drug-induced hyperkalemia: Impaired renal excretion of potassium; Extracellular potassium shift; Excessive potassium intake. The onset of action of Veltassa occurs 4 – 7 hours after administration. Mechanism of Action. Patiromer (VELTASSA ... Description/Mechanism of Action Patiromer is a non-absorbed cation exchange polymer of calcium-sorbitol that increases excretion of potassium by binding potassium in the gastrointestinal lumen, thereby reducing serum potassium levels. Drugs known to cause hyperkalemia and their mechanism of action 1,2 This helps prevent your body from absorbing too much potassium. Li L, Harrison SD, Cope MJ, et al. Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels. Veltassa (patiromer) is a potassium binder. The information and materials for Veltassa contained in this website were prepared based on the EU SmPC. Acute kidney injury is a rapid decrease in renal function over days to weeks, causing an accumulation of nitrogenous products in the blood (azotemia) with or without reduction in amount of urine output. Not systemically absorbed Redwood City, CA: Relypsa, Inc; 2016. Veltassa should not replace emergency treatment for life threatening hyperkalemia due to its delayed onset of action. The investigators envision that a strategy of simultaneously probing effect of a drug combined with analysis of mechanisms of action and predictive response will likely provide key information with which to design hard event (heart attack, stroke etc.) 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Veltassa is a non-absorbed, cation exchange polymer that contains a calcium-sorbitol counterion. Veltassa is used to treat hyperkalemia (high levels of potassium in your blood). Mechanism of Action. Veltassa (patiromer) is a medicine that binds itself to potassium in your digestive tract. Indication(s) Under Review in ... Veltassa [package insert]. Mechanism of action Sodium–potassium exchange resin (nonspecific) Calcium–potassium exchange polymer Crystalline compound that traps potassium in exchange for hydrogen and sodium cations Counterion content 100 mg sodium per gram of SPS 1600 mg calcium per 8.4 g patiromer 400 mg sodium per 5 g of SZC Cations bound Administration of Veltassa should be separated by 3 hours from other oral … Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC). based trials. Veltassa increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Table 1. The inactive ingredient is xanthan gum.